Lead Product(s) : Guanfacine
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Details : Guanfacine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Down Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Guanfacine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
Details : Guanfacine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2019
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Winthrop University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Guanfacine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prader-Willi Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2019
Lead Product(s) : Guanfacine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Winthrop University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Guanfacine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2018
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : SHIRE PLC | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable
Guanfacine Extended Release and Mindfulness Skills Therapy
Details : Guanfacine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stress Disorders, Post-Traumatic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 23, 2017
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : SHIRE PLC | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Columbia University | American Academy of Child Adolescent Psychiatry | SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
Details : Guanfacine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2014
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Columbia University | American Academy of Child Adolescent Psychiatry | SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Details : Guanfacine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Disruptive, Impulse Control, and Conduct Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2014
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Icahn School of Medicine at Mount Sinai | University of South Florida | SHIRE PLC | New York University
Deal Size : Inapplicable
Deal Type : Inapplicable
Guanfacine in Children With Tic Disorders
Details : Guanfacine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tourette Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2012
Lead Product(s) : Guanfacine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Icahn School of Medicine at Mount Sinai | University of South Florida | SHIRE PLC | New York University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Intuniv (Guanfacine HCl) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Intuniv
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 28, 2011
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Guanfacine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anxiety Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2011
Lead Product(s) : Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
